What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Pentose Phosphate Pathway: Steps and Purpose

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

The pentose phosphate pathway (PPP) is a cytosolic route of glucose-6-phosphate metabolism that runs in parallel with glycolysis and produces two products glycolysis cannot: NADPH, the reduced coenzyme used in reductive biosynthesis and antioxidant defense, and ribose-5-phosphate, the sugar backbone of nucleotides. It is often called the phosphate pentose pathway or simply the pp pathway, and unlike glycolysis it generates no ATP.

The pathway matters because it sits at the intersection of two problems every cell must solve. A dividing cell needs ribose for DNA and RNA, and a cell under oxidative stress needs a steady supply of reducing power to regenerate glutathione and keep reactive oxygen species in check. The PPP delivers both, and it does so without burning glucose all the way to carbon dioxide. In tissues as different as red blood cells, the heart, the immune system, and the intestinal epithelium, flux through this pathway is a direct readout of biosynthetic demand and redox pressure [1][2][3].

What Is the Pentose Phosphate Pathway?

The pentose phosphate pathway is a set of reversible and irreversible enzyme reactions that convert glucose-6-phosphate into NADPH, ribulose-5-phosphate, and a family of interconvertible sugar phosphates. It has two phases. The oxidative phase is irreversible and produces NADPH and ribulose-5-phosphate. The non-oxidative phase is reversible and rearranges carbon skeletons to make ribose-5-phosphate, glycolytic intermediates, or additional NADPH through recycling.

The pathway is cytosolic in most mammalian cells. Its seven enzymes operate in the cytoplasm, and the oxidative enzymes are the dominant source of cytosolic NADPH [1][4]. Some enzymes also appear in the endoplasmic reticulum of certain tissues, but the canonical pathway for NADPH production and nucleotide precursor supply is the cytosolic one [5].

A useful way to think about the PPP is as a metabolic valve. When a cell needs NADPH, the oxidative phase runs. When a cell needs ribose-5-phosphate, the non-oxidative phase runs in the direction that makes it. When a cell needs both, the two phases operate together in a cycle that regenerates glucose-6-phosphate and extracts more NADPH per glucose molecule [2].

Summary Table

Feature	Oxidative phase	Non-oxidative phase
Reversibility	Irreversible	Reversible
Main enzymes	G6PD, 6-phosphogluconolactonase, 6-phosphogluconate dehydrogenase	Transketolase, transaldolase, ribose-5-phosphate isomerase, ribulose-5-phosphate epimerase
Products	2 NADPH, 1 ribulose-5-phosphate, 1 CO2	Ribose-5-phosphate, fructose-6-phosphate, glyceraldehyde-3-phosphate, sedoheptulose-7-phosphate
Cofactor	NADP+	Thiamine pyrophosphate for transketolase
Regulation	G6PD is rate-limiting and inhibited by NADPH	Flux direction set by substrate and product concentrations
Main purpose	Reducing power and pentose phosphate	Carbon rearrangement for nucleotide and glycolytic intermediates
ATP yield	None	None

The Oxidative Phase: Two NADPH per Glucose-6-Phosphate

The oxidative phase is the committed, irreversible part of the pathway. It consumes one molecule of glucose-6-phosphate and produces two molecules of NADPH, one molecule of ribulose-5-phosphate, and one molecule of carbon dioxide.

Step 1: Glucose-6-Phosphate Dehydrogenase

Glucose-6-phosphate dehydrogenase (G6PD) oxidizes glucose-6-phosphate to 6-phosphogluconolactone, reducing NADP+ to NADPH in the process. This is the rate-limiting and regulated step of the entire pathway. G6PD is the enzyme that determines whether glucose-6-phosphate enters the oxidative PPP or stays in glycolysis, and its activity is the single most important control point for cytosolic NADPH production [1][6][7].

G6PD is inhibited by NADPH, its own product. When NADPH levels are high, the enzyme slows. When NADPH is consumed by antioxidant reactions or reductive biosynthesis, inhibition is relieved and flux increases. This feedback loop couples pathway activity directly to the redox state of the cell [4]. The enzyme is also regulated by transcription, by protein-protein interactions, and by phosphorylation in some systems [8][9].

Step 2: 6-Phosphogluconolactonase

6-phosphogluconolactonase hydrolyzes 6-phosphogluconolactone to 6-phosphogluconate. This is a lactone ring-opening reaction that does not produce NADPH. It is a necessary step because the lactone is unstable and the next enzyme requires the open-chain acid form. In many organisms the reaction proceeds spontaneously at a measurable rate, but the enzyme accelerates it and prevents accumulation of the reactive lactone intermediate [4].

Step 3: 6-Phosphogluconate Dehydrogenase

6-phosphogluconate dehydrogenase oxidizes 6-phosphogluconate to ribulose-5-phosphate, reducing a second NADP+ to NADPH and releasing carbon dioxide. This is the second and final NADPH-generating step of the oxidative phase. The enzyme is NADP-dependent and is distinct from the NAD-dependent dehydrogenases of the tricarboxylic acid cycle [4][10].

After these three steps, the oxidative phase has delivered two NADPH molecules and one ribulose-5-phosphate from a single glucose-6-phosphate. The carbon dioxide released comes from carbon 1 of glucose, which is why the pathway is sometimes measured by the release of 14CO2 from [1-14C]glucose-6-phosphate [11].

The Non-Oxidative Phase: Reversible Carbon Rearrangement

The non-oxidative phase does not produce NADPH directly. It rearranges the carbon skeletons of pentose phosphates into ribose-5-phosphate, fructose-6-phosphate, and glyceraldehyde-3-phosphate. These reactions are reversible, so the direction of flux depends on what the cell needs at that moment.

Ribulose-5-Phosphate Isomerase and Epimerase

Ribulose-5-phosphate can be converted to ribose-5-phosphate by ribulose-5-phosphate isomerase, or to xylulose-5-phosphate by ribulose-5-phosphate epimerase. Ribose-5-phosphate is the direct precursor for phosphoribosyl pyrophosphate (PRPP), which is required for purine and pyrimidine nucleotide synthesis. Xylulose-5-phosphate is the substrate for transketolase.

Transketolase

Transketolase (TKT) transfers a two-carbon unit from a ketose donor to an aldose acceptor. It uses thiamine pyrophosphate (TPP), a derivative of vitamin B1, as its cofactor. TPP binds in the active site and stabilizes the carbanion intermediate that carries the two-carbon fragment. Without adequate thiamine, transketolase activity falls, which is one reason thiamine deficiency affects tissues with high pentose phosphate flux [12].

Transketolase interconverts ribose-5-phosphate and xylulose-5-phosphate with sedoheptulose-7-phosphate and glyceraldehyde-3-phosphate. It is a key enzyme of the non-oxidative PPP, and its activity is required for the pentose cycle that amplifies NADPH yield when the pathway operates in recycling mode [2].

Transaldolase

Transaldolase (TALDO1) transfers a three-carbon unit from sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate, producing erythrose-4-phosphate and fructose-6-phosphate. Erythrose-4-phosphate can combine with xylulose-5-phosphate in a second transketolase reaction to produce fructose-6-phosphate and glyceraldehyde-3-phosphate. These products re-enter glycolysis or are recycled back to glucose-6-phosphate to generate more NADPH [2][3].

The non-oxidative phase is controlled largely by substrate availability and by the activity of transaldolase, which sets the rate and directionality of flux through this branch [3]. When ribose-5-phosphate accumulates, the pathway can shift toward recycling. When nucleotide synthesis consumes ribose-5-phosphate, the pathway shifts toward its production.

Pathway Logic at a Glance

The following flowchart shows the main decision path for glucose-6-phosphate entry into the pentose phosphate pathway and the two phases that follow.

flowchart TD
    A[Glucose 6 phosphate] --> B{G6PD active}
    B -->|NADPH low| C[Oxidative phase]
    B -->|NADPH high| D[Glycolysis]
    C --> E[6 phosphogluconolactone]
    E --> F[6 phosphogluconate]
    F --> G[Ribulose 5 phosphate]
    G --> H[Non oxidative phase]
    H --> I[Ribose 5 phosphate]
    H --> J[Fructose 6 phosphate]
    H --> K[Glyceraldehyde 3 phosphate]
    I --> L[Nucleotide synthesis]
    J --> D
    K --> D

Regulation: G6PD Is the Rate-Limiting Step

G6PD is the rate-limiting enzyme of the pentose phosphate pathway. Its activity determines how much glucose-6-phosphate enters the oxidative phase, and its inhibition by NADPH provides immediate feedback control. When NADPH is abundant, G6PD is inhibited and glucose-6-phosphate is diverted to glycolysis. When NADPH is consumed, inhibition is relieved and flux increases [4].

This regulation is not purely metabolic. G6PD expression and activity are modulated by hormones, growth factors, and stress signals. In the heart, exercise increases cytosolic NADPH by activating the PPP, and inhibition of PPP activity blunts exercise-induced cardiac hypertrophy [1]. In CD8+ T cells, non-oxidative PPP flux maintains NADPH homeostasis and supports activation, proliferation, and memory formation [2]. In peritoneal mesothelial cells, impaired branched-chain amino acid catabolism reduces G6PD expression and NADPH-generating capacity, linking metabolic stress to fibrosis [6].

The pathway also responds to oxidative stress. In Trypanosoma cruzi, G6PD is induced up to 46-fold by hydrogen peroxide, showing that the pathway is a stress-responsive system in some organisms [4]. In human keratinocytes, loss of 14-3-3σ promotes lysosomal degradation of G6PD and reduces antioxidant capacity after UVB exposure [7].

Purpose 1: NADPH for Antioxidant Defense

The most immediate purpose of the oxidative PPP is to supply NADPH for antioxidant defense. NADPH is the reducing coenzyme for glutathione reductase, which regenerates reduced glutathione (GSH) from oxidized glutathione (GSSG). GSH is the major small-molecule antioxidant in the cytosol, and it is used by glutathione peroxidase to detoxify hydrogen peroxide and lipid peroxides.

Red blood cells depend on this system more than almost any other cell type. They have no mitochondria, so they cannot use the mitochondrial NADPH-generating enzymes. They rely on the oxidative PPP to produce NADPH, and when G6PD activity is low, red blood cells become vulnerable to oxidative hemolysis. The pathway is also important in the heart, where PPP-derived NADPH protects against ischemia-reperfusion injury [1]. In the skin, PPP activity supports antioxidant capacity after UVB irradiation [7]. In the airway smooth muscle, G6PD expression influences the redox state and soluble guanylate cyclase function in asthma [13].

NADPH also supports reductive biosynthesis. Fatty acid synthesis, cholesterol synthesis, and some steps of neurotransmitter synthesis consume NADPH. In developing oilseed rape embryos, the oxidative PPP provides NADPH for fatty acid synthesis in plastids [11]. In CD8+ T cells, NADPH supports lipid synthesis and metabolic fitness [2].

Purpose 2: Ribose-5-Phosphate for Nucleotide Synthesis

The second major purpose of the PPP is to supply ribose-5-phosphate for nucleotide biosynthesis. Ribose-5-phosphate is converted to PRPP by PRPP synthetase, and PRPP is the activated sugar used in both purine and pyrimidine synthesis. Without a steady supply of ribose-5-phosphate, cells cannot make DNA or RNA, and proliferation stalls.

This is why the PPP is essential in dividing tissues. The colonic epithelium, one of the most proliferative tissues in the body, has high non-oxidative PPP capacity for converting ribose-5-phosphate to hexose and triose phosphates [14]. In CD8+ T cells, knockdown of transketolase or transaldolase causes ribose-5-phosphate accumulation, oxidative stress, and impaired proliferation [2]. In cancer cells, the PPP supports rapid proliferation and chemotherapy resistance. In pancreatic adenocarcinoma, ITGB4 expression correlates with PPP gene expression and gemcitabine resistance, and G6PD inhibition reduces NADPH and increases reactive oxygen species [15]. In lung adenocarcinoma, a transfer RNA-derived small RNA suppresses proliferation and metastasis by targeting G6PD mRNA [16].

The pathway also supplies ribose-5-phosphate for nucleotide synthesis in the malaria parasite, where the oxidative arm is geared for maximal NADP+ reduction and ribose-5-phosphate production during early development [12]. In Trypanosoma cruzi, the PPP is the major source of NADPH for trypanothione reduction, which is the parasite's main antioxidant defense [4].

Purpose 3: Carbon Recycling and Metabolic Flexibility

The non-oxidative phase gives the pathway flexibility that glycolysis alone cannot provide. When the cell needs more NADPH than ribose-5-phosphate, the non-oxidative enzymes can recycle pentose phosphates back into glucose-6-phosphate, which re-enters the oxidative phase. This pentose cycle amplifies NADPH yield per glucose molecule and is especially important in cells with high antioxidant demand [2].

When the cell needs more ribose-5-phosphate than NADPH, the non-oxidative phase can operate in the direction that produces ribose-5-phosphate from glycolytic intermediates. When the cell needs both, the pathway can run in a mixed mode. This flexibility is why the PPP is sometimes described as a metabolic hub rather than a simple linear pathway.

The pathway also connects to other metabolic routes. Erythrose-4-phosphate feeds into aromatic amino acid synthesis in bacteria and plants [10]. Xylulose-5-phosphate is a signaling molecule in some systems. Ribose-5-phosphate is used for biopterin synthesis, and activation of the non-oxidative PPP increases biopterin levels in microglial cells [17]. These connections make the PPP relevant beyond its two canonical products.

How the Pathway Is Studied in Practice

Researchers measure PPP activity in several ways. The oldest method uses the release of 14CO2 from [1-14C]glucose-6-phosphate, because carbon 1 is released as CO2 in the oxidative phase [11]. The ratio of 14CO2 from [1-14C]glucose to [6-14C]glucose gives an estimate of oxidative PPP flux relative to glycolysis.

Modern methods use isotopic tracing with 13C-labeled glucose and mass spectrometry to quantify flux through both phases. Metabolomic profiling can detect ribose-5-phosphate, sedoheptulose-7-phosphate, and other intermediates [2]. Genetically encoded fluorescent sensors can measure cytosolic NADPH in live cells, which allows real-time tracking of PPP activity in response to exercise or other stimuli [1].

Enzyme activity assays measure G6PD, 6-phosphogluconate dehydrogenase, transketolase, and transaldolase in cell lysates. G6PD activity is often normalized to total protein or to a housekeeping enzyme. Pharmacological inhibitors such as 6-aminonicotinamide and genetic knockdown of G6PD, TKT, or TALDO1 are used to test pathway function [2][7]. In cancer research, NADP+ and NADPH levels are measured with commercial kits, and reactive oxygen species are measured by flow cytometry to assess redox state [15].

Comparative and Clinical Relevance

The PPP is conserved across life, but its organization differs. In Escherichia coli, the pathway provides intermediates for amino acid, vitamin, nucleotide, and cell wall synthesis, and the oxidative branch is a major source of NADPH [10]. In Plasmodium falciparum, the pathway appears to use mainly the oxidative arm during early development, and the genes for transaldolase and NAD+ kinase are absent [12]. In Trypanosoma cruzi, the pathway is a potential drug target because the parasite depends on NADPH for oxidative defense [4]. In plants, the oxidative PPP in plastids supplies NADPH for fatty acid synthesis [11].

In humans, the pathway is relevant to many conditions. G6PD deficiency is the most common inherited enzyme disorder, and it illustrates how central the oxidative PPP is to red blood cell survival [18]. Beyond hemolysis, G6PD variants have been linked to changes in vascular gene expression and 3D genome organization [19]. The PPP is also implicated in autoimmune disease, liver disease, renal disease, cardiovascular disease, and aging [3]. In cancer, the pathway supports proliferation and resistance to chemotherapy, making it a target of active research [15][16][20].

Common Mistakes and Limitations

One common mistake is to treat the PPP as a minor side route of glucose metabolism. In reality, it is the main source of cytosolic NADPH in many cells and the only source of ribose-5-phosphate for nucleotide synthesis. Cells that lose PPP function cannot proliferate normally and are vulnerable to oxidative stress.

A second mistake is to assume the non-oxidative phase is irreversible. It is not. The direction of flux depends on substrate and product concentrations, and the pathway can run in either direction depending on whether the cell needs ribose-5-phosphate or NADPH.

A third mistake is to overlook the thiamine pyrophosphate requirement of transketolase. Thiamine deficiency impairs transketolase activity and can reduce non-oxidative PPP flux. This is a real consideration in nutrition and in some disease states [12].

A fourth mistake is to equate G6PD activity with total PPP flux. G6PD is rate-limiting for the oxidative phase, but non-oxidative flux can be high even when oxidative flux is low, and vice versa. Measuring only G6PD activity gives an incomplete picture [2][3].

A fifth mistake is to assume all NADPH comes from the PPP. Mitochondrial NADPH-generating enzymes, including malic enzyme and isocitrate dehydrogenase, also contribute. The PPP is the dominant cytosolic source, but it is not the only source [1].

Finally, individual variation matters. G6PD variants differ in activity, and the same variant can produce different phenotypes in different people. Clinical decisions about G6PD deficiency and related conditions require a veterinarian or physician who can interpret the specific case.

Quick Review

The pentose phosphate pathway is a cytosolic glucose-6-phosphate pathway that produces NADPH and ribose-5-phosphate.
The oxidative phase uses G6PD, 6-phosphogluconolactonase, and 6-phosphogluconate dehydrogenase to make two NADPH and one ribulose-5-phosphate per glucose-6-phosphate.
G6PD is the rate-limiting enzyme and is inhibited by NADPH.
The non-oxidative phase uses transketolase and transaldolase to interconvert pentose phosphates reversibly.
Transketolase requires thiamine pyrophosphate as a cofactor.
The pathway supports antioxidant defense, nucleotide synthesis, and reductive biosynthesis.
Red blood cells depend on the oxidative PPP for NADPH because they lack mitochondria.

Frequently Asked Questions

What is the pentose phosphate pathway in simple terms?

The pentose phosphate pathway is a cytosolic route that processes glucose-6-phosphate to make NADPH and ribose-5-phosphate. It runs alongside glycolysis and does not produce ATP.

What are the two phases of the pentose phosphate pathway?

The oxidative phase is irreversible and produces NADPH and ribulose-5-phosphate. The non-oxidative phase is reversible and rearranges sugar phosphates to make ribose-5-phosphate or glycolytic intermediates.

Why is G6PD important in the pentose phosphate pathway?

G6PD is the rate-limiting enzyme of the oxidative phase. It controls how much glucose-6-phosphate enters the pathway and is inhibited by NADPH, so it matches NADPH production to cellular demand.

What does the pentose phosphate pathway produce?

It produces NADPH, ribose-5-phosphate, and carbon dioxide. The non-oxidative phase also produces fructose-6-phosphate, glyceraldehyde-3-phosphate, and sedoheptulose-7-phosphate.

Why do red blood cells need the pentose phosphate pathway?

Red blood cells lack mitochondria, so they rely on the oxidative PPP for NADPH. NADPH regenerates reduced glutathione, which protects hemoglobin and membrane lipids from oxidative damage.

What cofactor does transketolase require?

Transketolase requires thiamine pyrophosphate, a derivative of vitamin B1. Without it, transketolase activity falls and non-oxidative PPP flux is impaired.